NASD · Healthcare · Biotechnology · USA
Harmony Biosciences Holdings Inc is a small cap company (market value between $300 million and $2 billion) in the Biotechnology industry.
Harmony Biosciences is a neuroscience company developing treatments for rare neurological diseases, including sleep/wake disorders and rare epilepsy. Its commercial product WAKIX (pitolisant) is an FDA-approved therapy for narcolepsy that works through a novel mechanism targeting histamine signaling in the brain. The company also pursues label expansions and next-generation formulations of pitolisant for other rare neurological conditions.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Harmony Biosciences Holdings Inc stock.
Undervalued: intrinsic value $105.17 per share, market price $33.01, margin of safety 68.6% (as of 2026-11-17).
Discounting its cash flows at 9.7% (average of 3 methods) values the shares at $105.17; the price of $33.01 is 69% below that value, and 75% of that value comes from beyond year five.
17 more funds hold it; the full list is part of the paid plan.
HRMY is undervalued (as of the 2026-11-17 close). Discounting its cash flows at 9.7% (average of 3 methods) values the shares at $105.17; the price of $33.01 is 69% below that value, and 75% of that value comes from beyond year five.
$105.17 per share (as of the 2026-11-17 close), against a market price of $33.01. That is a margin of safety of 68.6%. The value is the average of the 3 valuation methods that apply to this company, recomputed every night after the US close.